April 14, 2018 01:39 PM EDT
R&D

Al­ny­lam flags loom­ing FDA ap­pli­ca­tion for givosir­an, adding an­oth­er round of stel­lar ef­fi­ca­cy da­ta from ear­ly study

John Carroll

Editor & Founder

Al­ny­lam $AL­NY is buff­ing up its da­ta on givosir­an in an­tic­i­pa­tion of launch­ing an as­sault on an ac­cel­er­at­ed ap­proval lat­er in the year.

The biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times